Custom Search


Sunday 01 February 2004

Treatment of primary cutaneous follicular centre lymphoma with rituximab: A report of two cases.

By: Kennedy GA, Blum R, McCormack C, Prince HM.

Australas J Dermatol 2004 Feb;45(1):34-7

Rituximab (anti-CD20 chimeric monoclonal antibody) has been demonstrated to have significant activity in nodal B-cell lymphomas, with very few associated adverse effects. Although primary cutaneous B-cell lymphomas (PCBCL) also express the CD20 antigen, relatively few reports of rituximab use in PCBCL have been published to date. We present two cases of primary cutaneous follicular centre lymphoma treated with rituximab (375 mg/m2/week intravenously for 4 weeks). Both cases responded to rituximab, with one partial response and one complete response seen. No adverse effects were observed. To date, disease progression has occurred in one case during overall follow up at 6 and 17 months. The potential role of rituximab in the treatment of these lymphomas is discussed.

Use of this site is subject to the following terms of use